Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cbl-b-IN-3 is a potent proto-oncogene-B (CPL-B) inhibitor of casitas B-series lymphoma (ic50 < 1 nM). Cpl-b, a cyclic E3 ubiquitin protein ligase, is involved in the setting of T lymphocyte activation thresholds. Cpl-b negatively regulates p85 in an independent proteolytic manner, and participates in the recruitment of p85 to CD28 and T cell antigen receptor ζ through its E3 ubiquitin ligase activity. Inhibition of PI3K inhibits the enhancement of Cblb-/ -T cell activation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 383.00 | |
5 mg | In stock | $ 915.00 | |
10 mg | In stock | $ 1,250.00 | |
25 mg | In stock | $ 1,850.00 | |
50 mg | In stock | $ 2,480.00 | |
100 mg | In stock | $ 3,370.00 |
Description | Cbl-b-IN-3 is a potent proto-oncogene-B (CPL-B) inhibitor of casitas B-series lymphoma (ic50 < 1 nM). Cpl-b, a cyclic E3 ubiquitin protein ligase, is involved in the setting of T lymphocyte activation thresholds. Cpl-b negatively regulates p85 in an independent proteolytic manner, and participates in the recruitment of p85 to CD28 and T cell antigen receptor ζ through its E3 ubiquitin ligase activity. Inhibition of PI3K inhibits the enhancement of Cblb-/ -T cell activation. |
In vitro | Cbl-b-IN-3, augments the secretion of IL-2 by T-cells when stimulated with either an anti-CD3 antibody alone or in combination with an anti-CD28 antibody [1]. |
Molecular Weight | 537.62 |
Formula | C30H34F3N5O |
CAS No. | 2573775-59-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cbl-b-IN-3 2573775-59-2 Ubiquitination E1/E2/E3 Enzyme inhibitor inhibit